NEW YORK – Coriell Life Sciences and global professional services firm KPMG said today that they have entered into a partnership with to provide pharmacogenomics data to clinicians at the point of care. Thermo Fisher Scientific is contributing genetic analysis technology and clinical decision support content to the effort.
Terms of the deal were not announced.
Under the partnership, CLS will offer its Enterprise PGx platform system to clinicians, backed by Thermo Fisher data and a team of pharmacists, to assess genetic risks related to specific patients' prescribed medications and link that information to an institution's electronic health record system. KPMG's clinical intelligence platform will analyze that information to help clinicians develop suitable treatment plans for each patient, the companies said.
"This program quickly makes biomarker information available for doctors and nurses to help avoid drug-gene, drug-drug, or drug-disease interactions," Larry Burnett, advisory principal at KPMG LLP, the US-based accounting division of KPMG, said in a statement.
"The collaboration between KPMG and CLS will allow us to bring this powerful new science, combined with robust data analytics and healthcare optimization made possible through the use of Thermo Fisher's leading genetic analysis and next-generation sequencing technologies, to large population clients around the world," added Coriell Life Sciences CEO and President Scott Megill.
In April, Coriell Life Sciences partnered with RxGenomix to offer a pharmacogenomics training, implementation, and management package to healthcare providers.